Crysvita (burosumab-twza) Treatment
IRB-300004900
Approved small_molecule completed
Quick answer
Crysvita (burosumab-twza) Treatment for Epidermal Nevus Syndrome is a Approved program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Epidermal Nevus Syndrome
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed